Delix Therapeutics

Delix Therapeutics is a private, preclinical-stage biotech company developing a new generation of brain health medicines. Its core technology platform centers on neuroplastogens—small molecules designed to promote selective neuroplasticity and rewire neural circuits without the hallucinogenic effects or safety concerns of classic psychedelics. The company is targeting major neuropsychiatric disorders with a pipeline of novel compounds, positioning itself at the forefront of a potential paradigm shift in neuroscience. Backed by investors and led by a team experienced in neuroscience and drug development, Delix seeks to address the vast unmet need in mental health with scalable, non-hallucinogenic therapeutics.

Neuroplastogen Engine: A discovery platform for novel, non-hallucinogenic small molecules designed to promote selective neuroplasticity (growth of neural connections) to rewire circuits implicated in brain disorders.

Delix competes in the emerging neuroplastogen/psychoplastogen space. Direct competitors include other private companies (e.g., Lucy Discovery, Transcend Therapeutics) also developing non-hallucinogenic compounds. It also faces competition from companies advancing classic psychedelics (e.g., COMPASS Pathways, Cybin, Atai Life Sciences) and large pharma with interests in novel neuroscience mechanisms. Differentiation hinges on clinical efficacy, safety profile, and intellectual property.